{"filing":{"accession_number":"0001171843-26-004053","cik":"0001540159","ticker":"EDSA","company_name":"Edesa Biotech, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"f8k_061026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326004053/f8k_061026.htm"},"events":[{"id":5325,"run_id":4663,"accession_number":"0001171843-26-004053","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Edesa Biotech entered into a Securities Purchase Agreement on June 10, 2026, for a private placement of 729,241 common shares at $4.69–$5.21 per share, raising approximately $3.5 million. This unregistered equity issuance materially dilutes existing shareholders' ownership and increases the company's share count.","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6142,"accession_number":"0001171843-26-004053","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Edesa Biotech entered into a Securities Purchase Agreement on June 10, 2026, for a private placement of 729,241 common shares at $4.69–$5.21 per share, raising approximately $3.5 million. This is a classic dilutive equity issuance disclosed under Item 1.01. The unregistered sale of common stock to raise capital is material to investors as it increases share count and dilutes existing shareholders' ownership percentage.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:21:18.163548+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6143,"accession_number":"0001171843-26-004053","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly discloses unregistered sales of equity securities under a Purchase Agreement. The incorporation by reference to Item 1.01 (which typically covers material acquisitions or transactions) indicates a structured equity issuance. Unregistered equity sales are material to investors as they signal dilution and often indicate capital-raising activity at small- and mid-cap issuers like Edesa Biotech.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:21:18.163548+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6145,"accession_number":"0001171843-26-004053","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a \"Private Placement\" announced via press release on June 11, 2026. Private placements of equity securities are dilutive issuances that materially affect shareholder interests and capital structure. While the Item 7.01 disclosure itself is limited, the reference to a private placement announcement is a strong signal of dilutive equity issuance activity, which is material to investors assessing ownership dilution and cash-raising activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:21:18.163548+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6142,"accession_number":"0001171843-26-004053","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Edesa Biotech entered into a Securities Purchase Agreement on June 10, 2026, for a private placement of 729,241 common shares at $4.69–$5.21 per share, raising approximately $3.5 million. This is a classic dilutive equity issuance disclosed under Item 1.01. The unregistered sale of common stock to raise capital is material to investors as it increases share count and dilutes existing shareholders' ownership percentage.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:21:18.163548+00:00","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-06-11"},{"id":6143,"accession_number":"0001171843-26-004053","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly discloses unregistered sales of equity securities under a Purchase Agreement. The incorporation by reference to Item 1.01 (which typically covers material acquisitions or transactions) indicates a structured equity issuance. Unregistered equity sales are material to investors as they signal dilution and often indicate capital-raising activity at small- and mid-cap issuers like Edesa Biotech.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:21:18.163548+00:00","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-06-11"},{"id":6145,"accession_number":"0001171843-26-004053","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a \"Private Placement\" announced via press release on June 11, 2026. Private placements of equity securities are dilutive issuances that materially affect shareholder interests and capital structure. While the Item 7.01 disclosure itself is limited, the reference to a private placement announcement is a strong signal of dilutive equity issuance activity, which is material to investors assessing ownership dilution and cash-raising activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T13:21:18.163548+00:00","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-06-11"}]}